Baxter's $3.8 Billion Sale of Kidney Care Business to Carlyle Group
Tuesday, 13 August 2024, 06:43
Baxter's Kidney Care Business Sale
Baxter International has entered into a definitive agreement with Carlyle Group to sell its Kidney Care business for $3.8 billion.
Strategic Shift
- This agreement is part of Baxter's strategy to divest non-core assets.
- The decision aligns with plans first announced in January 2023.
Market Implications
The acquisition is expected to enhance investment and potentially lead to greater innovation in the renal care sector, marking a pivotal shift in the market landscape.
In conclusion, Baxter's divestiture of its Kidney Care business is a significant move aimed at streamlining operations and improving shareholder outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.